Compounds for the treatment of mTOR pathway related diseases

1. A method for the treatment of one or more mTOR pathway related diseases, the method comprising administering a therapeutically effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof, wherein

i) R 1 is alkyl, —CF 3 or CN, R 4 is selected from H, alkyl, halogen, alkoxy, —CF 3 , —OCF 3 , —SO 2 —CF 3 , —SO—CF 3 or —S—CF 3 and R 5 is independently selected from H, alkyl, halogen, —CF 3 or —CN; or

ii) R 1 is selected from H or halogen, R 4 is H, halogen, —S—CF 3 , —SOCF 3 or —SO 2 CF 3 , and

R 5 is independently selected from H, halogen, or —CN;

R 2 and R 3 are each independently selected from H, alkyl, halogen, —CF 3 or —CN;

R 6 is independently selected from H, alkyl, halogen, alkoxy, —CF 3 , —OCF 3 , —SO 2 CF 3 , —SOCF 3 or —SCF 3 ;

X is heteroatom, N(alkyl) or NH; and

n is 1 to 20; thereby treating the mTOR pathway related disease, wherein the mTOR pathway related disease is cancer selected from bladder cancer, kidney cancer, liver cancer, lung cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, stomach cancer, thyroid cancer, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma, Burkett's lymphoma, myelodysplastic syndrome, rhabdomyosarcoma, astrocytoma, neuroblastoma, schwannoma, seminoma, teratocarcinoma, osteosarcoma, or Kaposi's sarcoma.

2. The method of claim 1 , wherein,

R 1 is —CN, H or halogen;

R 2 is H or halogen;

R 3 is —CF 3 or halogen;

R 4 is —SCF 3 , —SOCF 3 , —SO 2 CF 3 , —OCF 3 , or —CF 3 ;

R 5 is H;

R 6 is alkyl;

X is O; and

n is 1 to 5.

3. The method of claim 1 , wherein R 4 is para to the amide moiety.

4. The method of claim 1 , wherein the compound of formula (I) is the (R)- or (S)-enantiomer or the racemate.

5. The method of claim 1 , wherein the compound of formula (I) is the (S)-enantiomer.

6. The method of claim 1 , wherein the compound of formula (I) is selected from any one of the following compounds:

wherein each of the above compounds is the (R)- or (S)-enantiomer, or the racemate, or a pharmaceutically acceptable salt, solvate or prodrug thereof.

7. The method of claim 1 , wherein the compound of formula (I) is

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

8. The method of claim 1 , wherein the compound of formula (I) is MPL (N-[(1S)-1-cyano-2-(5-cyano-2-trifluoromethyl-phenoxy)-1-methyl-ethyl]-4-trifluoromethylsulfanyl-benzamide):

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

9. The method of claim 1 , wherein the compound of formula (I) is monepantel sulphone (MPL-SO 2 ):

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

10. The method according to claim 1 , wherein the cancer is associated with a kinase.

11. The method according to claim 10 , wherein the kinase is a cyclin-dependent kinase.

12. The method according to claim 11 , wherein the cyclin-dependent kinase is cdk2 or cdk4.

13. The method of claim 1 wherein the therapeutically effective amount of a compound of formula (I) is administered in a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier.